These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19291635)

  • 21. Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
    Wienbergen H; Senges J; Gitt AK
    Diabetes Care; 2008 Feb; 31 Suppl 2():S222-5. PubMed ID: 18227489
    [No Abstract]   [Full Text] [Related]  

  • 22. Bringing JUPITER down to earth.
    Després JP
    Lancet; 2009 Apr; 373(9670):1147-8. PubMed ID: 19329179
    [No Abstract]   [Full Text] [Related]  

  • 23. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
    Colhoun H
    Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comment from the family practice viewpoint].
    Coradi B
    Praxis (Bern 1994); 2009 Feb; 98(3):131. PubMed ID: 19180439
    [No Abstract]   [Full Text] [Related]  

  • 25. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Bloom JM
    Lancet; 2009 Jul; 374(9683):25-6; author reply 26-7. PubMed ID: 19577688
    [No Abstract]   [Full Text] [Related]  

  • 27. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 30. [From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
    Márk L; Katona A
    Orv Hetil; 2009 Nov; 150(44):2012-8. PubMed ID: 19861287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The JUPITER study: background and research hypotheses].
    Rapezzi C; Gallo P
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):25S-27S. PubMed ID: 21298858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The JUPITER trial: How will it change clinical practice?
    Watson KE
    Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Primary prevention of cardiovascular disease].
    Gohlke H
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):38-43. PubMed ID: 15619173
    [No Abstract]   [Full Text] [Related]  

  • 34. C-reactive protein and cardiovascular risk: more fuel to the fire.
    Boekholdt SM; Kastelein JJ
    Lancet; 2010 Jan; 375(9709):95-6. PubMed ID: 20031200
    [No Abstract]   [Full Text] [Related]  

  • 35. Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
    Schooling CM; Au Yeung SL; Leung GM
    Eur J Clin Invest; 2014 Nov; 44(11):1135-40. PubMed ID: 25252212
    [No Abstract]   [Full Text] [Related]  

  • 36. Statins and aspirin: do they really work in women?
    Desai H; Hollingsworth PW; Chugh AR
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):151-62. PubMed ID: 25812803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
    Duvernoy CS; Blumenthal R
    Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
    [No Abstract]   [Full Text] [Related]  

  • 38. [JUPITER study, more reason to give statins as preventive measure - commentary].
    Narkiewicz K
    Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis.
    Dykun I; Mincu R; Hendricks S; Balcer B; Totzeck M; Rassaf T; Mahabadi AA
    Eur J Prev Cardiol; 2020 Oct; 27(15):1675-1678. PubMed ID: 31357886
    [No Abstract]   [Full Text] [Related]  

  • 40. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES; Canavan ME; Desai MM
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.